Regulus Therapeutics reported $2.49M in Selling and Administration Expenses for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Alnylam Pharmaceuticals ALNY:US $ 153.82M 1.08M
Arena Pharmaceuticals ARNA:US $ 31.94M 2.48M
Astrazeneca AZN:US 2.57B 76M
AstraZeneca AZN:LN 2.57B 76M
Biogen BIIB:US $ 637.3M 42.3M
Celldex Therapeutics CLDX:US $ 4.31M 185K
Dicerna Pharmaceuticals DRNA:US $ 25.46M 4.79M
Gilead Sciences GILD:US $ 1.34B 297M
GlaxoSmithKline GSK:LN 2.5B 183M
Intercept Pharmaceuticals ICPT:US $ 57.65M 1.62M
Intrexon XON:US $ 20M 1.3M
Lexicon Pharmaceuticals LXRX:US 7.94M 321K
Ligand Pharmaceuticals LGND:US $ 14.71M 2.09M
Merk MRK:US $ 2.25B 376M
Omeros OMER:US $ 21.56M 3.51M
Regulus Therapeutics RGLS:US $ 2.49M 10K
Sangamo Biosciences SGMO:US $ 16.49M 338K
Spectrum Pharmaceuticals SPPI:US $ 14.96M 642K
Takeda 4502:JP 219.84B 14.55B
Vital Therapies VTL:US $ 3.43M 17.44M
YTE INCY:US $ 168.86M 15.06M